Health

Geographic growth and the integration of the corporate-backed healthcare venture firm's newest partner is set to precede a busy year, Rob Coppedge and Hayley Hovious told Global Venturing.

The Global Corporate Venturing deal net rounds up the smaller investments from across the corporate innovation ecosystem.

The drug wholesaler’s CVC fund will have up to $39.3m in capital, and will be led by Suzuken's head of corporate strategy, Yuichi Yamamoto.

Web3 services provider Venly and genomic analysis technology provider Genome Insight each raised $23m while Rui Ye Lian helped Cedarlake Capital close a $189m fund.

The Takeda Vaccines spinoff floated in an upsized offering that granted its former parent $100m in shares.

Alphabet, Sanofi and Syncona were among the investors helping the drug developer advance toward clinical trials.

Migdal and Menora Mivtachim helped renewable energy infrastructure developer Fu-Gen with fresh funding which will help expand its operations in the UK and Finland. This is a deal from the renewable energy space, which continues to see much momentum in the context of energy transition.

Content personalisation technology provider Movable Ink and carbon-negative concrete developer Brimstone each raised $55m, with Intel and Amazon respectively among the investors.

Call centre software producer Replicant closed a $78m series B round backed by Salesforce Ventures while Ashvattha Therapeutics raised $69m from investors including strategic partner Huadong Medicine.

GS Group contributed to a series B round that pushed messenger RNA therapeutics and vaccine developer RVAC Medicines' overall funding to $140m.

Sector report: energy Q1 2022